To develop a safe and efficient Aβ vaccine for Alzheimer's disease, we constructed a plasmid DNA vaccine encoding ten repeats of Aβ3-10 and three copies of C3d-p28 as a molecular adjuvant and administered it intramuscularly in 12-month-old female Tg-APPswe/PSEN1dE9 mice. Therapeutic immunization with p(Aβ3-10)10-C3d-p28.3 stimulated a Th2 immune response that elicited therapeutic levels of anti-Aβ antibodies and improved cognitive function. In addition, the vaccine reduced the cerebral Aβ burden and astrocytosis without increasing the incidence of microhemorrhage. Our results indicate that the p(Aβ3-10)10-C3d-p28.3 vaccine is a promising immunotherapeutic option for Aβ vaccination in Alzheimer's disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neulet.2013.06.018 | DOI Listing |
Int J Dev Neurosci
October 1988
Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston 77550.
The specific activities of two forms of aryl acylamidase (AAA) were examined in 7 regions of the developing rat brain, plus the remainder of the brain and the whole brain. AAA-1 activity peaked at 15 days old in all brain regions studied except the whole brain where it peaked at 22 days of age. AAA-2 activity peaked between 15 and 29 days old in most brain regions studied except corpus striatum and hippocampus where the AAA-2 activity peaked before 15 days old.
View Article and Find Full Text PDF1. Two fractions of aryl acylamidase (EC 3.5.
View Article and Find Full Text PDF1. The serotonin (5-HT) sensitive brain aryl acylamidase (AAA) has received considerable attention due to its potential involvement in 5-HT action mechanism in CNS. 2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!